Aller au contenu

Maintenance et mise à jour des informations contenues dans l'application Orthodose

Résumé

Orthodose est une application médicale pionnière créée initialement en 2010 par un médecin spécialisé dans les soins palliatifs. Aujourd’hui, elle est développée et conçue par MEDLIGHT SRL pour offrir aux professionnels de la santé des informations précises sur la gestion de la douleur en soins palliatifs et les calculs de médicaments pertinents.


Dans un paysage inondé d’informations diverses, Orthodose se distingue en fournissant des informations alimentées par l’Evidence Based Medicine, mais qui restent pratiques, exploitables, utilisées par des pairs, facilitant des décisions thérapeutiques éclairées. Il est important de souligner qu’Orthodose fournit des informations théoriques à usage professionnel, dépourvues de diagnostics ou d’options de traitement spécifiques aux patients, ce qui souligne la nécessité pour les professionnels de la santé d’adapter les conseils d’application aux contextes individuels des patients.

Procédure visant à garantir la mise à jour et l'exactitude des informations relatives à l'application médicale

Afin de maintenir en permanence la qualité des informations fournies dans l’application Orthodose, nous avons élaboré une procédure spécifique visant à garantir que les informations médicales de l’application restent à jour et exactes. Notre objectif est de maintenir la fiabilité et l’efficacité d’Orthodose dans l’aide apportée aux professionnels de santé pour la prise en charge de la douleur dans le cadre des soins palliatifs.

Cycle de révision du contenu

Un cycle rigoureux de révision du contenu implique un expert clinique en soins palliatifs et inclut explicitement la supervision d’un médecin. Il garantit que les mises à jour et les évaluations du contenu médical de l’application sont supervisées par un professionnel de santé qualifié, ce qui renforce la crédibilité et la fiabilité de l’application. Ce cycle est conçu pour intégrer les dernières lignes directrices cliniques, les résultats de la recherche et les pratiques fondées sur des données probantes, avec des mises à jour annuelles ou plus fréquentes si nécessaire. Ce cycle reconnaît explicitement l’équilibre entre l’aspect pratique de l’application et la nécessité de la maintenir sécurisée et à jour, en veillant à ce que les décisions de mise à jour soient fondées non seulement sur les articles les plus récents, mais aussi sur leur applicabilité et leur sécurité dans le cadre d’une utilisation clinique.

Intégration du retour d'information de l'utilisateur

Le mécanisme d’intégration des commentaires des utilisateurs, recueillis par l’intermédiaire de l’application et du site web, est décrit plus en détail afin souligner son efficacité. Ce processus, mené mensuellement, consiste à examiner les commentaires afin d’identifier et de hiérarchiser les sources scientifiques et les besoins des mises à jour, renforçant ainsi la réactivité de l’application aux besoins des utilisateurs et améliorant son utilité pratique. L’inclusion des commentaires des utilisateurs dans le processus d’analyse documentaire et la décision de ne pas répertorier toutes les sources dans la bibliographie en raison de la longue durée de cette analyse (commencée il y a 15 ans) sont de nouveaux ajouts. Cette approche garantit une bibliographie relativement concise tout en restant complète.

Suivi de la littérature et des lignes directrices

Le suivi continu de la littérature scientifique, des directives cliniques et des mises à jour réglementaires est crucial. Ce processus implique une recherche continue de nouvelles informations relatives à la prise en charge de la douleur dans le cadre des soins palliatifs, afin de s’assurer que l’application reste une ressource actuelle et pratique pour les professionnels de la santé. Ce suivi inclut explicitement les critères de qualité, de praticité et de sécurité dans l’évaluation des nouvelles informations pour l’intégration de l’application, garantissant que les mises à jour ne reflètent pas seulement les dernières découvertes scientifiques, mais qu’elles sont également applicables et sûres dans le cadre d’une utilisation clinique standard.

Assurance qualité et validation

La section relative à l’assurance qualité et à la validation a été élargie pour détailler le processus de test par des « testeurs », notamment des médecins, afin de s’assurer que les mises à jour ne compromettent pas la fonctionnalité ou la fiabilité de l’application. Les utilisateurs souhaitant participer en tant que testeurs sont encouragés à poser leur candidature sur la page de contact d’Orthodose, afin de favoriser une approche communautaire du développement de l’application et de l’assurance qualité.

Journal des modifications et contrôle des versions

Avec l’historique détaillé de la création d’Orthodose et la gestion de MEDLIGHT SRL, l’application a subi des améliorations significatives pour consolider sa position en tant qu’outil informatif fiable, efficace et conforme pour les professionnels des soins palliatifs. L’approche de MEDLIGHT, qui comprend des cycles de mise à jour rigoureux, l’intégration des commentaires des utilisateurs, la surveillance continue de la littérature scientifique et une assurance qualité complète, établit une base solide pour la confiance des utilisateurs. Cet engagement en faveur de l’excellence et de la sécurité des patients est désormais souligné dans les notes de version de notre journal des modifications, reflétant notre engagement à maintenir Orthodose comme une ressource de premier ordre pour les professionnels de la santé. En incorporant ces procédures détaillées, MEDLIGHT SRL s’assure qu’Orthodose continue d’être un outil d’information ciblée fiable et efficace, favorisant une plus grande confiance et démontrant un engagement inébranlable envers la qualité et la sécurité des patients en soins palliatifs.

Bibliographie

La bibliographie sera compilée de manière sélective afin de refléter l’examen approfondi de la littérature sur plus de 15 ans, en mettant l’accent sur les références clés qui informent le contenu de l’application, telles que :

  • Cherny, Nathan I., and others (eds), Oxford Textbook of Palliative Medicine, 6 edn (Oxford, 2021; online edn, Oxford Academic, 1 Aug. 2021), https://doi.org/10.1093/med/9780198821328.001.0001, accessed 1 Apr. 2024.

  • Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., Haugen, D. F., Juhl, G., King, S., Klepstad, P., Laugsand, E. A., Maltoni, M., Mercadante, S., Nabal, M., Pigni, A., Radbruch, L., … European Association for Palliative Care (EAPC) (2012). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet. Oncology13(2), e58–e68. https://doi.org/10.1016/S1470-2045(12)70040-2

  • Nelson, K. A., Glare, P. A., Walsh, D., & Groh, E. S. (1997). A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. Journal of pain and symptom management13(5), 262–267. https://doi.org/10.1016/s0885-3924(96)00329-6

  • Cole, S. G., Brozinsky, S., & Isenberg, J. I. (1983). Midazolam, a new more potent benzodiazepine, compared with diazepam: a randomized, double-blind study of preendoscopic sedatives. Gastrointestinal endoscopy29(3), 219–222. https://doi.org/10.1016/s0016-5107(83)72588-5

  • Schuster, M., Bayer, O., Heid, F., & Laufenberg-Feldmann, R. (2018). Opioid Rotation in Cancer Pain Treatment. Deutsches Arzteblatt international115(9), 135–142. https://doi.org/10.3238/arztebl.2018.0135

  • Alford, D. P., Compton, P., & Samet, J. H. (2006). Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Annals of internal medicine144(2), 127–134. https://doi.org/10.7326/0003-4819-144-2-200601170-00010

  • McKenzie, C. A., McKinnon, W., Naughton, D. P., Treacher, D., Davies, G., Phillips, G. J., & Hilton, P. J. (2005). Differentiating midazolam over-sedation from neurological damage in the intensive care unit. Critical care (London, England)9(1), R32–R36. https://doi.org/10.1186/cc3010

  • Lugo, R. A., Satterfield, K. L., & Kern, S. E. (2005). Pharmacokinetics of methadone. Journal of pain & palliative care pharmacotherapy19(4), 13–24.

  • Sittl, R., Nuijten, M., & Poulsen Nautrup, B. (2006). Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany. Clinical therapeutics28(8), 1144–1154. https://doi.org/10.1016/j.clinthera.2006.08.002

  • Derendorf, H., Möllmann, H., Barth, J., Möllmann, C., Tunn, S., & Krieg, M. (1991). Pharmacokinetics and oral bioavailability of hydrocortisone. Journal of clinical pharmacology31(5), 473–476. https://doi.org/10.1002/j.1552-4604.1991.tb01906.x

  • Heazelwood, V. J., Galligan, J. P., Cannell, G. R., Bochner, F., & Mortimer, R. H. (1984). Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. British journal of clinical pharmacology17(1), 55–59. https://doi.org/10.1111/j.1365-2125.1984.tb04999.x

  • Spoorenberg, S. M., Deneer, V. H., Grutters, J. C., Pulles, A. E., Voorn, G. P., Rijkers, G. T., Bos, W. J., & van de Garde, E. M. (2014). Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. British journal of clinical pharmacology78(1), 78–83. https://doi.org/10.1111/bcp.12295

  • Pöyhiä, R., Seppälä, T., Olkkola, K. T., & Kalso, E. (1992). The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. British journal of clinical pharmacology33(6), 617–621. https://doi.org/10.1111/j.1365-2125.1992.tb04090.x

  • Navigante, A. H., Cerchietti, L. C., Castro, M. A., Lutteral, M. A., & Cabalar, M. E. (2006). Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of pain and symptom management31(1), 38–47. https://doi.org/10.1016/j.jpainsymman.2005.06.009

  • Sandouk, P., Serrie, A., Scherrmann, J. M., Langlade, A., & Bourre, J. M. (1991). Presence of morphine metabolites in human cerebrospinal fluid after intracerebroventricular administration of morphine. European journal of drug metabolism and pharmacokineticsSpec No 3, 166–171.

  • Baker, J., Dickman, A., Mason, S., & Ellershaw, J. (2018). The current evidence base for the feasibility of 48-hour continuous subcutaneous infusions (CSCIs): A systematically-structured review. PloS one13(3), e0194236. https://doi.org/10.1371/journal.pone.0194236

  • Moksnes, K., Dale, O., Rosland, J. H., Paulsen, O., Klepstad, P., & Kaasa, S. (2011). How to switch from morphine or oxycodone to methadone in cancer patients? a randomised clinical phase II trial. European journal of cancer (Oxford, England : 1990)47(16), 2463–2470. https://doi.org/10.1016/j.ejca.2011.06.047

  • Klimas, R., & Mikus, G. (2014). Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. British journal of anaesthesia113(6), 935–944. https://doi.org/10.1093/bja/aeu186

  • Westerling, D., Höglund, P., Lundin, S., & Svedman, P. (1994). Transdermal administration of morphine to healthy subjects. British journal of clinical pharmacology37(6), 571–576. https://doi.org/10.1111/j.1365-2125.1994.tb04306.x

  • Donnelly R. F. (2009). Physical compatibility and chemical stability of ketamine-morphine mixtures in polypropylene syringes. The Canadian journal of hospital pharmacy62(1), 28–33. https://doi.org/10.4212/cjhp.v62i1.114

  • Bloomfield, S. S., Cissell, G. B., Mitchell, J., Barden, T. P., Kaiko, R. F., Fitzmartin, R. D., Grandy, R. P., Komorowski, J., & Goldenheim, P. D. (1993). Analgesic efficacy and potency of two oral controlled-release morphine preparations. Clinical pharmacology and therapeutics53(4), 469–478. https://doi.org/10.1038/clpt.1993.53

  • Edge, W. G., Cooper, G. M., & Morgan, M. (1979). Analgesic effects of sublingual buprenorphine. Anaesthesia34(5), 463–467. https://doi.org/10.1111/j.1365-2044.1979.tb06325.x

  • Morrow, S. A., Stoian, C. A., Dmitrovic, J., Chan, S. C., & Metz, L. M. (2004). The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology63(6), 1079–1080. https://doi.org/10.1212/01.wnl.0000138572.82125.f5

  • Bao, Y. J., Hou, W., Kong, X. Y., Yang, L., Xia, J., Hua, B. J., & Knaggs, R. (2016). Hydromorphone for cancer pain. The Cochrane database of systematic reviews10(10), CD011108. https://doi.org/10.1002/14651858.CD011108.pub2

  • Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., Haugen, D. F., Juhl, G., King, S., Klepstad, P., Laugsand, E. A., Maltoni, M., Mercadante, S., Nabal, M., Pigni, A., Radbruch, L., … European Association for Palliative Care (EAPC) (2012). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet. Oncology13(2), e58–e68. https://doi.org/10.1016/S1470-2045(12)70040-2

  • Ofoegbu, A., & B Ettienne, E. (2021). Pharmacogenomics and Morphine. Journal of clinical pharmacology61(9), 1149–1155. https://doi.org/10.1002/jcph.1873

  • Wittwer, E., & Kern, S. E. (2006). Role of morphine’s metabolites in analgesia: concepts and controversies. The AAPS journal8(2), E348–E352. https://doi.org/10.1007/BF02854905

  • Watanabe, S., Pereira, J., Tarumi, Y., Hanson, J., & Bruera, E. (2008). A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain. Journal of palliative medicine11(4), 570–574. https://doi.org/10.1089/jpm.2007.0176

  • De Gregori, S., De Gregori, M., Ranzani, G. N., Allegri, M., Minella, C., & Regazzi, M. (2012). Morphine metabolism, transport and brain disposition. Metabolic brain disease27(1), 1–5. https://doi.org/10.1007/s11011-011-9274-6

  • Takahashi, M., Ohara, T., Yamanaka, H., Shimada, A., Nakaho, T., & Makoto, Y. (2003). The oral-to-intravenous equianalgesic ratio of morphine based on plasma concentrations of morphine and metabolites in advanced cancer patients receiving chronic morphine treatment. Palliative medicine17(8), 673–678. https://doi.org/10.1191/0269216303pm824oa

  • Hagen, N. A., & Babul, N. (1997). Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer79(7), 1428–1437.

  • Lasheen, W., Walsh, D., Mahmoud, F., Sarhill, N., Rivera, N., Davis, M., Lagman, R., & Legrand, S. (2010). The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain. Palliative medicine24(1), 9–16. https://doi.org/10.1177/0269216309346595

  • Poulain, P., Berleur, M. P., Lefki, S., Lefebvre, D., Chvetzoff, G., Serra, E., Tremellat, F., Derniaux, A., Filbet, M., & EQUIMETH2 Study Group (2016). Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-Related Pain: The EQUIMETH2 Trial (Methadone for Cancer-Related Pain). Journal of pain and symptom management52(5), 626–636.e1. https://doi.org/10.1016/j.jpainsymman.2016.05.022

  • Link, B., Haschke, M., Grignaschi, N., Bodmer, M., Aschmann, Y. Z., Wenk, M., & Krähenbühl, S. (2008). Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping. British journal of clinical pharmacology66(4), 473–484. https://doi.org/10.1111/j.1365-2125.2008.03201.x

  • Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008). Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta neurologica Scandinavica118(2), 69–86. https://doi.org/10.1111/j.1600-0404.2008.01004.x

  • Pecking, M., Montestruc, F., Marquet, P., Wodey, E., Homery, M. C., & Dostert, P. (2002). Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers. British journal of clinical pharmacology54(4), 357–362. https://doi.org/10.1046/j.1365-2125.2002.01665.x

  • Gálvez, R., Schäfer, M., Hans, G., Falke, D., & Steigerwald, I. (2013). Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study. Advances in therapy30(3), 229–259. https://doi.org/10.1007/s12325-013-0015-6

  • Scott, L. J., Lyseng-Williamson, K. A., & Garnock-Jones, K. P. (2012). Oromucosal midazolam: a guide to its use in paediatric patients with prolonged acute convulsive seizures. CNS drugs26(10), 893–897. https://doi.org/10.2165/11209350-000000000-00000

  • Bruera, E., Pereira, J., Watanabe, S., Belzile, M., Kuehn, N., & Hanson, J. (1996). Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer78(4), 852–857. https://doi.org/10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T

  • Spénard, J., Caillé, G., de Montigny, C., Vézina, M., Ouellette, J., Larivière, L., & Trudel, F. (1988). Placebo-controlled comparative study of the anxiolytic activity and of the pharmacokinetics of oral and sublingual lorazepam in generalized anxiety. Biopharmaceutics & drug disposition9(5), 457–464. https://doi.org/10.1002/bod.2510090504

  • Moulin, D. E., Kreeft, J. H., Murray-Parsons, N., & Bouquillon, A. I. (1991). Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet (London, England)337(8739), 465–468. https://doi.org/10.1016/0140-6736(91)93401-t

  • Whitwam, J. G., Al-Khudhairi, D., & McCloy, R. F. (1983). Comparison of midazolam and diazepam in doses of comparable potency during gastroscopy. British journal of anaesthesia55(8), 773–777. https://doi.org/10.1093/bja/55.8.773

  • Zilker, M., Sörgel, F., & Holzgrabe, U. (2019). A systematic review of the stability of finished pharmaceutical products and drug substances beyond their labeled expiry dates. Journal of pharmaceutical and biomedical analysis166, 222–235. https://doi.org/10.1016/j.jpba.2019.01.016

  • Simpson, R. J., Power, K. G., Wallace, L. A., Butcher, M. H., Swanson, V., & Simpson, E. C. (1990). Controlled comparison of the characteristics of long-term benzodiazepine users in general practice. The British journal of general practice : the journal of the Royal College of General Practitioners40(330), 22–26.

  • Waldmann, C. S., Eason, J. R., Rambohul, E., & Hanson, G. C. (1984). Serum morphine levels. A comparison between continuous subcutaneous infusion and continuous intravenous infusion in postoperative patients. Anaesthesia39(8), 768–771. https://doi.org/10.1111/j.1365-2044.1984.tb06520.x

  • Stuart-Harris, R., Joel, S. P., McDonald, P., Currow, D., & Slevin, M. L. (2000). The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. British journal of clinical pharmacology49(3), 207–214. https://doi.org/10.1046/j.1365-2125.2000.00141.x

  • Patel, M., Taskar, K. S., & Zamek-Gliszczynski, M. J. (2016). Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites. Journal of clinical pharmacology56 Suppl 7, S23–S39. https://doi.org/10.1002/jcph.671

  • Kokubun, H., Yoshimoto, T., Hojo, M., Fukumura, K., & Matoba, M. (2014). Pharmacokinetics of oxycodone after intravenous and subcutaneous administration in Japanese patients with cancer pain. Journal of pain & palliative care pharmacotherapy28(4), 338–350. https://doi.org/10.3109/15360288.2014.969872

  • Elkader, A., & Sproule, B. (2005). Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clinical pharmacokinetics44(7), 661–680. https://doi.org/10.2165/00003088-200544070-00001

  • Moulin, D. E., Kreeft, J. H., Murray-Parsons, N., & Bouquillon, A. I. (1991). Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet (London, England)337(8739), 465–468. https://doi.org/10.1016/0140-6736(91)93401-t

  • Imanaka, K., Tominaga, Y., Etropolski, M., Ohashi, H., Hirose, K., & Matsumura, T. (2014). Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release. Clinical drug investigation34(7), 501–511. https://doi.org/10.1007/s40261-014-0204-3

  • Allwood M. The stability of diamorphine alone and in combination with anti-emetics in plastic syringes. Palliative Medicine. 1991;5(4):330-333. doi:10.1177/026921639100500409

  • Quigley C. (2004). Opioid switching to improve pain relief and drug tolerability. The Cochrane database of systematic reviews, (3), CD004847. https://doi.org/10.1002/14651858.CD004847

  • Ni, Y., Gao, H., Ouyang, W., Yang, G., Cheng, M., & Ding, L. (2024). Pharmacokinetics, metabolite profiling, safety and tolerability of YZJ-4729 tartrate, a novel G protein-biased μ-opioid receptor agonist, in healthy Chinese subjects. Frontiers in pharmacology14, 1295319. https://doi.org/10.3389/fphar.2023.1295319

  • Wiffen, P. J., Edwards, J. E., Barden, J., & McQuay, H. J. (2003). Oral morphine for cancer pain. The Cochrane database of systematic reviews, (4), CD003868. https://doi.org/10.1002/14651858.CD003868

  • King, S., Forbes, K., Hanks, G. W., Ferro, C. J., & Chambers, E. J. (2011). A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliative medicine25(5), 525–552. https://doi.org/10.1177/0269216311406313

  • Vacha, M. E., Huang, W., & Mando-Vandrick, J. (2015). The role of subcutaneous ketorolac for pain management. Hospital pharmacy50(2), 108–112. https://doi.org/10.1310/hpj5002-108

  • Fleming, K., & Donnelly, R. F. (2019). Physical Compatibility and Chemical Stability of Injectable and Oral Ranitidine Solutions. Hospital pharmacy54(1), 32–36. https://doi.org/10.1177/0018578718763085

  • Dahan, A., Yassen, A., Romberg, R., Sarton, E., Teppema, L., Olofsen, E., & Danhof, M. (2006). Buprenorphine induces ceiling in respiratory depression but not in analgesia. British journal of anaesthesia96(5), 627–632. https://doi.org/10.1093/bja/ael051

  • Connock, M., Juarez-Garcia, A., Jowett, S., Frew, E., Liu, Z., Taylor, R. J., Fry-Smith, A., Day, E., Lintzeris, N., Roberts, T., Burls, A., & Taylor, R. S. (2007). Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health technology assessment (Winchester, England)11(9), 1–iv. https://doi.org/10.3310/hta11090

  • Alford, D. P., Compton, P., & Samet, J. H. (2006). Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Annals of internal medicine144(2), 127–134. https://doi.org/10.7326/0003-4819-144-2-200601170-00010

  • Reddy, A., Vidal, M., Stephen, S., Baumgartner, K., Dost, S., Nguyen, A., Heung, Y., Kwan, S., Wong, A., Pangemanan, I., Azhar, A., Tayjasanant, S., Rodriguez, E., Waletich, J., Lim, K. H., Wu, J., Liu, D., Williams, J., Yennurajalingam, S., & Bruera, E. (2017). The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients. Journal of pain and symptom management54(3), 280–288. https://doi.org/10.1016/j.jpainsymman.2017.07.001

  • Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. (2022). National Institute for Health and Care Excellence (NICE).

  • Rosenblum, A., Cruciani, R. A., Strain, E. C., Cleland, C. M., Joseph, H., Magura, S., Marsch, L. A., McNicholas, L. F., Savage, S. R., Sundaram, A., & Portenoy, R. K. (2012). Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. Journal of opioid management8(6), 369–382. https://doi.org/10.5055/jom.2012.0137

  • Mercadante, S., Porzio, G., Fulfaro, F., Aielli, F., Verna, L., Ficorella, C., Casuccio, A., Riina, S., Intravaia, G., & Mangione, S. (2007). Switching from transdermal drugs: an observational « N of 1 » study of fentanyl and buprenorphine. Journal of pain and symptom management34(5), 532–538. https://doi.org/10.1016/j.jpainsymman.2007.01.006

  • Likar R. (2006). Transdermal buprenorphine in the management of persistent pain – safety aspects. Therapeutics and clinical risk management2(1), 115–125.

  • Hale, M., Garofoli, M., & Raffa, R. B. (2021). Benefit-Risk Analysis of Buprenorphine for Pain Management. Journal of pain research14, 1359–1369. https://doi.org/10.2147/JPR.S305146

  • Sittl, R., Likar, R., & Nautrup, B. P. (2005). Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clinical therapeutics27(2), 225–237. https://doi.org/10.1016/j.clinthera.2005.02.012

  • Bullingham, R. E., O’Sullivan, G., McQuay, H. J., Poppleton, P., Rolfe, M., Weir, L., & Moore, R. A. (1984). Mandatory sublingual buprenorphine for postoperative pain. Anaesthesia39(4), 329–334. https://doi.org/10.1111/j.1365-2044.1984.tb07272.x

  • Soltani, G., Khorsand, M., Shamloo, A. S., Jarahi, L., & Zirak, N. (2015). Comparison of Intravenous Morphine with Sublingual Buprenorphine in Management of Postoperative Pain after Closed Reduction Orthopedic Surgery. The archives of bone and joint surgery3(4), 280–285.

  • Drover D. R. (2004). Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clinical pharmacokinetics43(4), 227–238. https://doi.org/10.2165/00003088-200443040-00002

  • Cherny N. (2011). Is oral methadone better than placebo or other oral/transdermal opioids in the management of pain?. Palliative medicine25(5), 488–493. https://doi.org/10.1177/0269216310397687

  • James, I. G., O’Brien, C. M., & McDonald, C. J. (2010). A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. Journal of pain and symptom management40(2), 266–278. https://doi.org/10.1016/j.jpainsymman.2010.01.013

  • Mercadante, S., Casuccio, A., Tirelli, W., & Giarratano, A. (2009). Equipotent doses to switch from high doses of opioids to transdermal buprenorphine. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer17(6), 715–718. https://doi.org/10.1007/s00520-008-0546-6

  • Choudhury, K., Dasgupta, P., Paul, N., Choudhury, K. B., Roy, B., & Maity, S. (2018). A Comparative Study of Transdermal Buprenorphine and Oral Morphine in the Treatment of Chronic Pain of Malignant Origin. Indian journal of palliative care24(4), 500–504. https://doi.org/10.4103/IJPC.IJPC_83_18

  • Vermeire, A., & Remon, J. P. (1999). Stability and compatibility of morphine. International journal of pharmaceutics187(1), 17–51. https://doi.org/10.1016/s0378-5173(99)00181-7

  • Elkader, A., & Sproule, B. (2005). Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clinical pharmacokinetics44(7), 661–680. https://doi.org/10.2165/00003088-200544070-00001

  • Darwish, M., Kirby, M., Robertson, P., Jr, Hellriegel, E., & Jiang, J. G. (2006). Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clinical pharmacokinetics45(8), 843–850. https://doi.org/10.2165/00003088-200645080-00006

  • Schneider, J. J., Good, P., & Ravenscroft, P. J. (2006). Effect of tubing on loss of clonazepam administered by continuous subcutaneous infusion. Journal of pain and symptom management31(6), 563–567. https://doi.org/10.1016/j.jpainsymman.2005.09.008

  • Watson, D. G., Lin, M., Morton, A., Cable, C. G., & McArthur, D. A. (2005). Compatibility and stability of dexamethasone sodium phosphate and ketamine hydrochloride subcutaneous infusions in polypropylene syringes. Journal of pain and symptom management30(1), 80–86. https://doi.org/10.1016/j.jpainsymman.2005.01.018

  • Caraceni, A., Pigni, A., & Brunelli, C. (2011). Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliative medicine25(5), 402–409. https://doi.org/10.1177/0269216310392102

  • King, S., Forbes, K., Hanks, G. W., Ferro, C. J., & Chambers, E. J. (2011). A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliative medicine25(5), 525–552. https://doi.org/10.1177/0269216311406313

  • Dickman, A., Bickerstaff, M., Jackson, R., Schneider, J., Mason, S., & Ellershaw, J. (2017). Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability. BMC palliative care16(1), 22. https://doi.org/10.1186/s12904-017-0195-y

  • Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., Haugen, D. F., Juhl, G., King, S., Klepstad, P., Laugsand, E. A., Maltoni, M., Mercadante, S., Nabal, M., Pigni, A., Radbruch, L., … European Association for Palliative Care (EAPC) (2012). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet. Oncology13(2), e58–e68. https://doi.org/10.1016/S1470-2045(12)70040-2

  • Vallner, J. J., Stewart, J. T., Kotzan, J. A., Kirsten, E. B., & Honigberg, I. L. (1981). Pharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjects. Journal of clinical pharmacology21(4), 152–156. https://doi.org/10.1002/j.1552-4604.1981.tb05693.x

  • King, S., Forbes, K., Hanks, G. W., Ferro, C. J., & Chambers, E. J. (2011). A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliative medicine25(5), 525–552. https://doi.org/10.1177/0269216311406313

  • Babul, N., & Darke, A. C. (1992). Putative role of hydromorphone metabolites in myoclonus. Pain51(2), 260–261. https://doi.org/10.1016/0304-3959(92)90270-L

  • Darwish, M., Kirby, M., Robertson, P., Jr, Tracewell, W., & Jiang, J. G. (2006). Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clinical therapeutics28(5), 707–714. https://doi.org/10.1016/j.clinthera.2006.05.015

  • Mercadante, S., & Caraceni, A. (2011). Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliative medicine25(5), 504–515. https://doi.org/10.1177/0269216311406577

  • Inoue, S., Saito, Y., Tsuneto, S., Aruga, E., Ogata, T., & Uemori, M. (2018). A double-blind, randomized comparative study to investigate the morphine to hydromorphone conversion ratio in Japanese cancer patients. Japanese journal of clinical oncology48(5), 442–449. https://doi.org/10.1093/jjco/hyy046

  • Wittwer, E., & Kern, S. E. (2006). Role of morphine’s metabolites in analgesia: concepts and controversies. The AAPS journal8(2), E348–E352. https://doi.org/10.1007/BF02854905

  • Reddy, A., Vidal, M., Stephen, S., Baumgartner, K., Dost, S., Nguyen, A., Heung, Y., Kwan, S., Wong, A., Pangemanan, I., Azhar, A., Tayjasanant, S., Rodriguez, E., Waletich, J., Lim, K. H., Wu, J., Liu, D., Williams, J., Yennurajalingam, S., & Bruera, E. (2017). The Conversion Ratio From Intravenous Hydromorphone to Oral Opioids in Cancer Patients. Journal of pain and symptom management54(3), 280–288. https://doi.org/10.1016/j.jpainsymman.2017.07.001

  • Bruera, E., Sloan, P., Mount, B., Scott, J., & Suarez-Almazor, M. (1996). A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediate-release hydromorphone in patients with cancer pain. Canadian Palliative Care Clinical Trials Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology14(5), 1713–1717. https://doi.org/10.1200/JCO.1996.14.5.1713

  • Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., Haugen, D. F., Juhl, G., King, S., Klepstad, P., Laugsand, E. A., Maltoni, M., Mercadante, S., Nabal, M., Pigni, A., Radbruch, L., … European Association for Palliative Care (EAPC) (2012). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet. Oncology13(2), e58–e68. https://doi.org/10.1016/S1470-2045(12)70040-2

  • Davis, M. P., & Walsh, D. (2001). Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer9(2), 73–83. https://doi.org/10.1007/s005200000180

  • Baumrucker, S. J., Jbara, M., & Rogers, R. M. (2016). A new mathematical approach to methadone conversion. Journal of pharmacology & pharmacotherapeutics7(2), 93–95. https://doi.org/10.4103/0976-500X.184773

  • Ferrari, A., Coccia, C. P., Bertolini, A., & Sternieri, E. (2004). Methadone–metabolism, pharmacokinetics and interactions. Pharmacological research50(6), 551–559. https://doi.org/10.1016/j.phrs.2004.05.002

  • Fainsinger, R., Schoeller, T., & Bruera, E. (1993). Methadone in the management of cancer pain: a review. Pain52(2), 137–147. https://doi.org/10.1016/0304-3959(93)90125-9

  • Verebely, K., & Kutt, H. (1975). Methadone plasma levels in maintenance patients: the effect of dose omission. Research communications in chemical pathology and pharmacology11(3), 373–386.

  • Jiang, H., Hillhouse, M., Du, J., Pan, S., Alfonso, A., Wang, J., Zhou, Z., Yuan, W., Ling, W., & Zhao, M. (2016). Dose, Plasma Level, and Treatment Outcome Among Methadone Patients in Shanghai, China. Neuroscience bulletin32(6), 538–544. https://doi.org/10.1007/s12264-016-0059-0

  • Bosilkovska, M., Walder, B., Besson, M., Daali, Y., & Desmeules, J. (2012). Analgesics in patients with hepatic impairment: pharmacology and clinical implications. Drugs72(12), 1645–1669. https://doi.org/10.2165/11635500-000000000-00000

  • Säwe, J., Hansen, J., Ginman, C., Hartvig, P., Jakobsson, P. A., Nilsson, M. I., Rane, A., & Anggård, E. (1981). Patient-controlled dose regimen of methadone for chronic cancer pain. British medical journal (Clinical research ed.)282(6266), 771–773. https://doi.org/10.1136/bmj.282.6266.771

  • Caraceni, A., Hanks, G., Kaasa, S., Bennett, M. I., Brunelli, C., Cherny, N., Dale, O., De Conno, F., Fallon, M., Hanna, M., Haugen, D. F., Juhl, G., King, S., Klepstad, P., Laugsand, E. A., Maltoni, M., Mercadante, S., Nabal, M., Pigni, A., Radbruch, L., … European Association for Palliative Care (EAPC) (2012). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet. Oncology13(2), e58–e68. https://doi.org/10.1016/S1470-2045(12)70040-2

  • Benítez-Rosario, M. A., Salinas-Martín, A., Aguirre-Jaime, A., Pérez-Méndez, L., & Feria, M. (2009). Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors. Journal of pain and symptom management37(6), 1061–1068. https://doi.org/10.1016/j.jpainsymman.2008.05.016

  • Inoue, S., Saito, Y., Tsuneto, S., Aruga, E., Ogata, T., & Uemori, M. (2018). A double-blind, randomized comparative study to investigate the morphine to hydromorphone conversion ratio in Japanese cancer patients. Japanese journal of clinical oncology48(5), 442–449. https://doi.org/10.1093/jjco/hyy046

  • Ferry, J. J., Horvath, A. M., Bekersky, I., Heath, E. C., Ryan, C. F., & Colburn, W. A. (1988). Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. Journal of clinical pharmacology28(1), 81–87. https://doi.org/10.1002/j.1552-4604.1988.tb03105.x

  • Mercadante, S., Porzio, G., Ferrera, P., Fulfaro, F., Aielli, F., Verna, L., Villari, P., Ficorella, C., Gebbia, V., Riina, S., Casuccio, A., & Mangione, S. (2008). Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. European journal of pain (London, England)12(8), 1040–1046. https://doi.org/10.1016/j.ejpain.2008.01.013

  • Mercadante, S., Casuccio, A., & Calderone, L. (1999). Rapid switching from morphine to methadone in cancer patients with poor response to morphine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology17(10), 3307–3312. https://doi.org/10.1200/JCO.1999.17.10.3307

  • Porta-Sales, J., Garzón-Rodríguez, C., Villavicencio-Chávez, C., Llorens-Torromé, S., & González-Barboteo, J. (2016). Efficacy and Safety of Methadone as a Second-Line Opioid for Cancer Pain in an Outpatient Clinic: A Prospective Open-Label Study. The oncologist21(8), 981–987. https://doi.org/10.1634/theoncologist.2015-0503

  • Morita, T., Takigawa, C., Onishi, H., Tajima, T., Tani, K., Matsubara, T., Miyoshi, I., Ikenaga, M., Akechi, T., Uchitomi, Y., & Japan Pain, Rehabilitation, Palliative Medicine, and Psycho-Oncology (PRPP) Study Group (2005). Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial. Journal of pain and symptom management30(1), 96–103. https://doi.org/10.1016/j.jpainsymman.2004.12.010

  • Centeno, C., & Vara, F. (2005). Intermittent subcutaneous methadone administration in the management of cancer pain. Journal of pain & palliative care pharmacotherapy19(2), 7–12.

  • Mathew, P., & Storey, P. (1999). Subcutaneous methadone in terminally ill patients: manageable local toxicity. Journal of pain and symptom management18(1), 49–52. https://doi.org/10.1016/s0885-3924(99)00020-2

  • Fallon, M. T., & Laird, B. J. (2011). A systematic review of combination step III opioid therapy in cancer pain: an EPCRC opioid guideline project. Palliative medicine25(5), 597–603. https://doi.org/10.1177/0269216310392101

  • Zimmermann, C., Seccareccia, D., Booth, C. M., & Cottrell, W. (2005). Rotation to methadone after opioid dose escalation: How should individualization of dosing occur?. Journal of pain & palliative care pharmacotherapy19(2), 25–31.

  • Hagen, N. A., & Wasylenko, E. (1999). Methadone: outpatient titration and monitoring strategies in cancer patients. Journal of pain and symptom management18(5), 369–375. https://doi.org/10.1016/s0885-3924(99)00083-4

  • Lukin, B., Greenslade, J., Kearney, A. M., Douglas, C., Howell, T., Barras, M., & Good, P. (2020). Conversion of other opioids to methadone: a retrospective comparison of two methods. BMJ supportive & palliative care10(2), 201–204. https://doi.org/10.1136/bmjspcare-2018-001645

  • Moksnes, K., Kaasa, S., Paulsen, Ø., Rosland, J. H., Spigset, O., & Dale, O. (2012). Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain. European journal of clinical pharmacology68(8), 1147–1156. https://doi.org/10.1007/s00228-012-1228-3

  • Stielow, M., Witczyńska, A., Kubryń, N., Fijałkowski, Ł., Nowaczyk, J., & Nowaczyk, A. (2023). The Bioavailability of Drugs-The Current State of Knowledge. Molecules (Basel, Switzerland)28(24), 8038. https://doi.org/10.3390/molecules28248038

  • Blackburn D 2005) Methadone: the analgesic. European Journal of Palliative Care. 12: 188-191.

  • Rowley, D., McLean, S., O’Gorman, A., Ryan, K., & McQuillan, R. (2011). Review of cancer pain management in patients receiving maintenance methadone therapy. The American journal of hospice & palliative care28(3), 183–187. https://doi.org/10.1177/1049909110380897

  • Sugiyama, Y., Sakamoto, N., Ohsawa, M., Onizuka, M., Ishida, K., Murata, Y., Iio, A., Sugano, K., Maeno, K., Takeyama, H., Akechi, T., & Kimura, K. (2016). A Retrospective Study on the Effectiveness of Switching to Oral Methadone for Relieving Severe Cancer-Related Neuropathic Pain and Limiting Adjuvant Analgesic Use in Japan. Journal of palliative medicine19(10), 1051–1059. https://doi.org/10.1089/jpm.2015.0303

  • Fisher, K., Stiles, C., & Hagen, N. A. (2004). Characterization of the early pharmacodynamic profile of oral methadone for cancer-related breakthrough pain: a pilot study. Journal of pain and symptom management28(6), 619–625. https://doi.org/10.1016/j.jpainsymman.2004.03.003

  • Heiskanen, T., & Kalso, E. (1997). Controlled-release oxycodone and morphine in cancer related pain. Pain73(1), 37–45. https://doi.org/10.1016/s0304-3959(97)00072-9

  • Bruera, E., Belzile, M., Pituskin, E., Fainsinger, R., Darke, A., Harsanyi, Z., Babul, N., & Ford, I. (1998). Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. Journal of clinical oncology : official journal of the American Society of Clinical Oncology16(10), 3222–3229. https://doi.org/10.1200/JCO.1998.16.10.3222

  • Curtis, G. B., Johnson, G. H., Clark, P., Taylor, R., Brown, J., O’Callaghan, R., Shi, M., & Lacouture, P. G. (1999). Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. European journal of clinical pharmacology55(6), 425–429. https://doi.org/10.1007/s002280050651

  • Lauretti, G. R., Oliveira, G. M., & Pereira, N. L. (2003). Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. British journal of cancer89(11), 2027–2030. https://doi.org/10.1038/sj.bjc.6601365

  • Kalso, E., Pöyhiä, R., Onnela, P., Linko, K., Tigerstedt, I., & Tammisto, T. (1991). Intravenous morphine and oxycodone for pain after abdominal surgery. Acta anaesthesiologica Scandinavica35(7), 642–646. https://doi.org/10.1111/j.1399-6576.1991.tb03364.x

  • Silvasti, M., Rosenberg, P., Seppälä, T., Svartling, N., & Pitkänen, M. (1998). Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia. Acta anaesthesiologica Scandinavica42(5), 576–580. https://doi.org/10.1111/j.1399-6576.1998.tb05169.x

  • Nicholson, A. B., Watson, G. R., Derry, S., & Wiffen, P. J. (2017). Methadone for cancer pain. The Cochrane database of systematic reviews2(2), CD003971. https://doi.org/10.1002/14651858.CD003971.pub4

  • Huddart, R., Clarke, M., Altman, R. B., & Klein, T. E. (2018). PharmGKB summary: oxycodone pathway, pharmacokinetics. Pharmacogenetics and genomics28(10), 230–237. https://doi.org/10.1097/FPC.0000000000000351

  • Charles, B., Hardy, J., Anderson, H., Tapuni, A., George, R., & Norris, R. (2014). Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer22(2), 325–330. https://doi.org/10.1007/s00520-013-1973-6

  • Leow, K. P., Smith, M. T., Williams, B., & Cramond, T. (1992). Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clinical pharmacology and therapeutics52(5), 487–495. https://doi.org/10.1038/clpt.1992.176

  • Dahan, A., Yassen, A., Romberg, R., Sarton, E., Teppema, L., Olofsen, E., & Danhof, M. (2006). Buprenorphine induces ceiling in respiratory depression but not in analgesia. British journal of anaesthesia96(5), 627–632. https://doi.org/10.1093/bja/ael051

  • Kleine-Brueggeney, M., Musshoff, F., Stuber, F., & Stamer, U. M. (2010). Pharmacogenetics in palliative care. Forensic science international203(1-3), 63–70. https://doi.org/10.1016/j.forsciint.2010.07.003

  • Westdorp, H., Kuip, E. J. M., van Oort, I. M., Kramers, C., Gerritsen, W. R., & Vissers, K. C. P. (2018). Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer. Journal of pain and symptom management55(4), e6–e8. https://doi.org/10.1016/j.jpainsymman.2017.11.016

  • Baker, J., Dickman, A., Mason, S., Bickerstaff, M., Jackson, R., McArdle, A., Lawrence, I., Stephenson, F., Paton, N., Kirk, J., Waters, B., & Ellershaw, J. (2020). An evaluation of continuous subcutaneous infusions across seven NHS acute hospitals: is there potential for 48-hour infusions?. BMC palliative care19(1), 99. https://doi.org/10.1186/s12904-020-00611-3

  • Cheung, K. C., Bouvy, M. L., & De Smet, P. A. (2009). Medication errors: the importance of safe dispensing. British journal of clinical pharmacology67(6), 676–680. https://doi.org/10.1111/j.1365-2125.2009.03428.x

  • Kornick, C. A., Santiago-Palma, J., Khojainova, N., Primavera, L. H., Payne, R., & Manfredi, P. L. (2001). A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer92(12), 3056–3061. https://doi.org/10.1002/1097-0142(20011215)92:12<3056::aid-cncr10166>3.0.co;2-h

  • Carlson C. L. (2016). Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review. Journal of pain research9, 515–534. https://doi.org/10.2147/JPR.S97759

  • Treillet, E., Laurent, S., & Hadjiat, Y. (2018). Practical management of opioid rotation and equianalgesia. Journal of pain research11, 2587–2601. https://doi.org/10.2147/JPR.S170269

  • Nelson, K. A., Glare, P. A., Walsh, D., & Groh, E. S. (1997). A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. Journal of pain and symptom management13(5), 262–267. https://doi.org/10.1016/s0885-3924(96)00329-6

  • Spoorenberg, S. M., Deneer, V. H., Grutters, J. C., Pulles, A. E., Voorn, G. P., Rijkers, G. T., Bos, W. J., & van de Garde, E. M. (2014). Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. British journal of clinical pharmacology78(1), 78–83. https://doi.org/10.1111/bcp.12295

  • Al-Tannak, N. F., Cable, C. G., McArthur, D. A., & Watson, D. G. (2012). A stability indicating assay for a combination of morphine sulphate with levomepromazine hydrochloride used in palliative care. Journal of clinical pharmacy and therapeutics37(1), 71–73. https://doi.org/10.1111/j.1365-2710.2011.01252.x

  • Donnelly R. F. (2009). Physical compatibility and chemical stability of ketamine-morphine mixtures in polypropylene syringes. The Canadian journal of hospital pharmacy62(1), 28–33. https://doi.org/10.4212/cjhp.v62i1.114

  • Storm, M. C., Broyles, J. E., Herrera, O. R., & Helms, R. A. (2022). Stability of 4 Intravenous Drug Formulations in Prefilled Syringes Stored Frozen for Up to 60 Days. Hospital pharmacy57(1), 61–68. https://doi.org/10.1177/0018578720973880

  • Barcia, E., Reyes, R., Luz Azuara, M., Sánchez, Y., & Negro, S. (2003). Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer11(2), 107–113. https://doi.org/10.1007/s00520-002-0415-7

  • Fielding, H., Kyaterekera, N., Skellern, G. G., Tettey, J. N., McDade, J. R., Msuya, Z., Watson, D. G., & Urie, J. (2000). The compatibility and stability of octreotide acetate in the presence of diamorphine hydrochloride in polypropylene syringes. Palliative medicine14(3), 205–207. https://doi.org/10.1191/026921600666997498

  • Grassby, P. F., & Hutchings, L. (1997). Drug combinations in syringe drivers: the compatibility and stability of diamorphine with cyclizine and haloperidol. Palliative medicine11(3), 217–224. https://doi.org/10.1177/026921639701100306

  • Simpson, R. J., Power, K. G., Wallace, L. A., Butcher, M. H., Swanson, V., & Simpson, E. C. (1990). Controlled comparison of the characteristics of long-term benzodiazepine users in general practice. The British journal of general practice : the journal of the Royal College of General Practitioners40(330), 22–26.

  • Beigmohammadi, M. T., Hanifeh, M., Rouini, M. R., Sheikholeslami, B., & Mojtahedzadeh, M. (2013). Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill Patients. Iranian journal of pharmaceutical research : IJPR12(2), 483–488.

  • Lau, M. H., Hackman, C., & Morgan, D. J. (1998). Compatibility of ketamine and morphine injections. Pain75(2-3), 389–390. https://doi.org/10.1016/s0304-3959(97)00176-0

  • Negro, S., Azuara, M. L., Sánchez, Y., Reyes, R., & Barcia, E. (2002). Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer10(1), 65–70. https://doi.org/10.1007/s005200100303

  • Mucci-LoRusso, P., Berman, B. S., Silberstein, P. T., Citron, M. L., Bressler, L., Weinstein, S. M., Kaiko, R. F., Buckley, B. J., & Reder, R. F. (1998). Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. European journal of pain (London, England)2(3), 239–249. https://doi.org/10.1016/s1090-3801(98)90020-9

  • Dickman, A., Bickerstaff, M., Jackson, R., Schneider, J., Mason, S., & Ellershaw, J. (2017). Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability. BMC palliative care16(1), 22. https://doi.org/10.1186/s12904-017-0195-y

  • Liu, S., Liu, X., Chen, S., Xiao, Y., & Zhuang, W. (2017). Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials. PloS one12(11), e0188644. https://doi.org/10.1371/journal.pone.0188644

  • Storey, P., Hill, H. H., Jr, St Louis, R. H., & Tarver, E. E. (1990). Subcutaneous infusions for control of cancer symptoms. Journal of pain and symptom management5(1), 33–41. https://doi.org/10.1016/s0885-3924(05)80007-7

  • Bruera, E., Palmer, J. L., Bosnjak, S., Rico, M. A., Moyano, J., Sweeney, C., Strasser, F., Willey, J., Bertolino, M., Mathias, C., Spruyt, O., & Fisch, M. J. (2004). Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology22(1), 185–192. https://doi.org/10.1200/JCO.2004.03.172

  • Malinoff, H. L., Barkin, R. L., & Wilson, G. (2005). Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. American journal of therapeutics12(5), 379–384. https://doi.org/10.1097/01.mjt.0000160935.62883.ff

  • McLean, S., & Twomey, F. (2015). Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence. Journal of pain and symptom management50(2), 248–59.e1. https://doi.org/10.1016/j.jpainsymman.2015.02.029

  • Cuschieri, R. J., Morran, C. G., & McArdle, C. S. (1984). Comparison of morphine and sublingual buprenorphine following abdominal surgery. British journal of anaesthesia56(8), 855–859. https://doi.org/10.1093/bja/56.8.855

  • Treillet, E., Laurent, S., & Hadjiat, Y. (2018). Practical management of opioid rotation and equianalgesia. Journal of pain research11, 2587–2601. https://doi.org/10.2147/JPR.S170269

  • Biancofiore G. (2006). Oxycodone controlled release in cancer pain management. Therapeutics and clinical risk management2(3), 229–234. https://doi.org/10.2147/tcrm.2006.2.3.229

  • Jäppinen, A., Kokki, H., Naaranlahti, T. J., & Rasi, A. S. (1999). Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. Pharmacy world & science : PWS21(6), 272–274. https://doi.org/10.1023/a:1008771621812¥

  •  Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. (2022). National Institute for Health and Care Excellence (NICE).

  • Nadeau, S. E., Wu, J. K., & Lawhern, R. A. (2021). Opioids and Chronic Pain: An Analytic Review of the Clinical Evidence. Frontiers in pain research (Lausanne, Switzerland)2, 721357. https://doi.org/10.3389/fpain.2021.721357

  • Reynolds, L., Rauck, R., Webster, L., DuPen, S., Heinze, E., Portenoy, R., Katz, N., Charapata, S., Wallace, M., & Fisher, D. M. (2004). Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. Pain110(1-2), 182–188. https://doi.org/10.1016/j.pain.2004.03.024

  • Beaver, W. T., & Feise, G. A. (1978). A comparison of the analgesic effect of intramuscular nalbuphine and morphine in patients with postoperative pain. The Journal of pharmacology and experimental therapeutics204(2), 487–496.

  • Kaiko, R. F., Wallenstein, S. L., Rogers, A., Grabinski, P., & Houde, R. W. (1981). Relative analgesic potency of intramuscular heroin and morphine in cancer patients with postoperative pain and chronic pain due to cancer. NIDA research monograph34, 213–219.

  • White, C., Hardy, J., Boyd, A., & Hall, A. (2008). Subcutaneous sufentanil for palliative care patients in a hospital setting. Palliative medicine22(1), 89–90. https://doi.org/10.1177/0269216307085177

  • Davis M. P. (2004). Acute pain in advanced cancer: an opioid dosing strategy and illustration. The American journal of hospice & palliative care21(1), 47–50. https://doi.org/10.1177/104990910402100111

  • Dickman, Andrew, Drugs in Palliative Care, 3 edn (Oxford, 2023; online edn, Oxford Academic, 1 Feb. 2023) https://www.pharmaceuticalpress.com/product/palliativecareformularypcf8/

  • Davis, M. P., Weissman, D. E., & Arnold, R. M. (2004). Opioid dose titration for severe cancer pain: a systematic evidence-based review. Journal of palliative medicine7(3), 462–468. https://doi.org/10.1089/1096621041349581

  • Dundee, J. W., Loan, W. B., & Clarke, R. S. (1966). Studies of drugs given before anaesthesia. XI. Diamorphine (heroin) and morphine. British journal of anaesthesia38(8), 610–619. https://doi.org/10.1093/bja/38.8.610

  • Kissin, I., Bright, C. A., & Bradley, E. L., Jr (2000). Acute tolerance to continuously infused alfentanil: the role of cholecystokinin and N-methyl-D-aspartate-nitric oxide systems. Anesthesia and analgesia91(1), 110–116. https://doi.org/10.1097/00000539-200007000-00021

  • Davis, M. P., Weissman, D. E., & Arnold, R. M. (2004). Opioid dose titration for severe cancer pain: a systematic evidence-based review. Journal of palliative medicine7(3), 462–468. https://doi.org/10.1089/1096621041349581

  • Charlesworth, S. (Ed.). (2022). Palliative Care Formulary (8th ed.). Pharmaceutical Press, https://www.pharmaceuticalpress.com/product/palliativecareformularypcf8/

  • Willens, J. S., & Myslinski, N. R. (1993). Pharmacodynamics, pharmacokinetics, and clinical uses of fentanyl, sufentanil, and alfentanil. Heart & lung : the journal of critical care22(3), 239–251.

  • Kwon, Y. S., Jang, J. S., Lee, N. R., Kim, S. S., Kim, Y. K., Hwang, B. M., Kang, S. S., Son, H. J., & Lim, S. Y. (2016). A Comparison of Oxycodone and Alfentanil in Intravenous Patient-Controlled Analgesia with a Time-Scheduled Decremental Infusion after Laparoscopic Cholecystectomy. Pain research & management2016, 7868152. https://doi.org/10.1155/2016/7868152

  • Cran, A., Dorman, S., & Kirkham, S. (2017). Opioid rotation to alfentanil: comparative evaluation of conversion ratios. BMJ supportive & palliative care7(3), 265–266. https://doi.org/10.1136/bmjspcare-2017-001349

  • White, C., Hardy, J., Boyd, A., & Hall, A. (2008). Subcutaneous sufentanil for palliative care patients in a hospital setting. Palliative medicine22(1), 89–90. https://doi.org/10.1177/0269216307085177

  • Kaiko, R. F., Wallenstein, S. L., Rogers, A., Grabinski, P., & Houde, R. W. (1981). Relative analgesic potency of intramuscular heroin and morphine in cancer patients with postoperative pain and chronic pain due to cancer. NIDA research monograph34, 213–219.

  • Alizadeh, S., Mahmoudi, G. A., Solhi, H., Sadeghi-Sedeh, B., Behzadi, R., & Kazemifar, A. M. (2015). Post-operative Analgesia in Opioid Dependent Patients: Comparison of Intravenous Morphine and Sublingual Buprenorphine. Addiction & health7(1-2), 60–65.

  • Autres :
    https://www.benzoinfo.com
    https://www.benzo.org.uk/index.htm
    https://www.sciencedirect.com/book/9780323847025
    https://www.pharmaceuticalpress.com/products/palliative-care-formulary/
    https://cbip.be/fr/
    https://www.fda.gov
    Adult Drug Information Handbook, 32 th edition, American Pharmacists Association (APhA), Wolters Kluwer Edition.

Télécharger la bibliographie